MOBERG PHARMA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE
Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announces that the prospectus relating to the Company’s rights issue of units consisting of ordinary shares and warrants (the “Rights Issue”) has been approved and registered by the Swedish Financial Supervisory Authority and is available in Swedish on the Company’s website www.mobergpharma.se/investerare/prospekt and will also be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,